Citation Impact
Citing Papers
Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study
2019
Cancer Treatment–Induced Bone Loss in Breast and Prostate Cancer
2008
Protein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade
2017 Standout
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
2018
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
2009 Standout
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
2016 Standout
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
2013 StandoutScienceNobel
Oncogenic activation of the Notch1 gene by deletion of its promoter in Ikaros-deficient T-ALL
2010 StandoutNobel
Cancer statistics, 2022
2022 Standout
Best Practices in Adolescent and Young Adult Patients with Acute Lymphoblastic Leukemia: A Focus on Asparaginase
2015
Caloric restriction leads to high marrow adiposity and low bone mass in growing mice
2010
Cancer statistics, 2023
2023 Standout
Cancer statistics, 2020
2020 Standout
Cancer statistics, 2024
2024 Standout
Cancer treatment and survivorship statistics, 2022
2022 Standout
Cancer Statistics, 2021
2021 Standout
Down-Regulation of Na+/K+ATPase Activity by Human Parvovirus B19 Capsid Protein VP1
2013 Standout
Recent advances in the management of AL Amyloidosis
2015
Post-remission therapy for acute myeloid leukemia
2014
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
2013 Standout
Characteristics of bortezomib‐ and thalidomide‐induced peripheral neuropathy
2008
Acute lymphoblastic leukaemia
2008
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
Management of gram-positive bacterial infections in patients with cancer
2011
New treatment for acute myelogenous leukemia
2014
Marine natural products
1990 Standout
Systematic review of oral cryotherapy for the management of oral mucositis in cancer patients and clinical practice guidelines
2019
BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines
2018
Therapeutic management of adrenal insufficiency
2009
Drug-Induced Hepatotoxicity
2003 Standout
Inflammaging: a new immune–metabolic viewpoint for age-related diseases
2018 Standout
Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes
2018 StandoutNobel
Case Report: Ticlopidine-Induced Cholestatic Hepatitis Report of Three Cases and Review of the Literature
1998
Survivors of childhood and adolescent cancer: life-long risks and responsibilities
2013 Standout
Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline
2016 Standout
Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis
2014 Standout
Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial
2007
Human FoxP3+ regulatory T cells in systemic autoimmune diseases
2011 StandoutNobel
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
2006 Standout
Inflammation and tumor progression: signaling pathways and targeted intervention
2021 Standout
Acute Myeloid Leukemia and the Position of Autologous Stem Cell Transplantation
2007
Human parvovirus B19 infection in acute fulminant liver failure
1999
Challenges in the Management of Burkitt's Lymphoma
2002
From the Sea to Anticancer Therapy
2011
Targeting apoptosis in cancer therapy
2020 Standout
Continuous Subcutaneous Hydrocortisone Infusion Therapy in Addison's Disease: A Randomized, Placebo-Controlled Clinical Trial
2014
The many faces of small B cell lymphomas with plasmacytic differentiation and the contribution of MYD88 testing
2015
Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma
2013
Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
2013
Pathogenesis and treatment of renal failure in multiple myeloma
2008
Regulatory T cells in diabetes and gastritis
2009
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
2010 Standout
What We Talk About When We Talk About Fat
2014 Standout
Declining rates of treatment-related mortality in patients with newly diagnosed AML given ‘intense’ induction regimens: a report from SWOG and MD Anderson
2013
Mitochondria as multifaceted regulators of cell death
2019 Standout
The biology and therapy of adult acute lymphoblastic leukemia
2003
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy
2020 Standout
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
2014 Standout
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
2014 Standout
Optimal therapy for acute lymphoblastic leukemia in adolescents and young adults
2011
Treatment of Multiple Myeloma: A Comprehensive Review
2009
Antiretroviral Treatment of Adult HIV Infection
2012 Standout
Didemnins, tamandarins and related natural products
2012
Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma
2010
Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy
2017
The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal
2017
Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America
2014 Standout
Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia
2016
Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461
2006
Trends in survival of patients with Burkitt lymphoma/leukemia in the USA: an analysis of 3691 cases
2013
Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy
2014
Efficacy and Safety of Vincristine Sulfate Liposome Injection in the Treatment of Adult Acute Lymphocytic Leukemia
2016
Biology, Risk Stratification, and Therapy of Pediatric Acute Leukemias: An Update
2011
Acute Myeloid Leukemia
2015 Standout
Raltegravir-Based HAART Regimen in a Patient with Large B-Cell Lymphoma
2009
Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial
2010
Clinical Trial Participation and Time to Treatment Among Adolescents and Young Adults With Cancer: Does Age at Diagnosis or Insurance Make a Difference?
2011
The myth of the second remission of acute leukemia in the adult
2012
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
2009 Standout
Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation
2012
Guidelines for the Management of Pediatric and Adult Tumor Lysis Syndrome: An Evidence-Based Review
2008 Standout
AIDS-Related Malignancies
2003
Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial
2010
Individualizing Treatment of Patients With Myeloma in the Era of Novel Agents
2008
Proteasome dysfunction triggers activation of SKN-1A/Nrf1 by the aspartic protease DDI-1
2016 StandoutNobel
Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits
2015
Cytokine Storm
2020 Standout
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
2018 Standout
Toward the potential cure of leukemias in the next decade
2018
The impact of natural selection on health and disease: uses of the population genetics approach in humans
2013
Cancer treatment and survivorship statistics, 2016
2016 Standout
Marrow Fat and Bone—New Perspectives
2013
Metabolic reprogramming and cancer progression
2020 StandoutScience
Cancer treatment and survivorship statistics, 2019
2019 Standout
Reduction of Retrovirus-Induced Immunosuppression by In Vivo Modulation of T Cells during Acute Infection
2004 StandoutNobel
Plant Secondary Metabolites as Anticancer Agents: Successes in Clinical Trials and Therapeutic Application
2018 Standout
Multiple Myeloma
2011 Standout
Acute myeloid leukaemia
2016
CAR T cell immunotherapy for human cancer
2018 StandoutScience
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
2016 Standout
Hypomethylation and up-regulation ofPD-1in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation
2015
Cancer treatment and survivorship statistics, 2014
2014 Standout
Works of Albert Oriol being referenced
Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
2012
Serum Pepsinogen I: An Early Marker of Pernicious Anemia in Patients with Type 1 Diabetes
2005
Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma
2013
High‐dose chemotherapy and immunotherapy in adult Burkitt lymphoma
2008
Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group
2010
Acute Lymphoblastic Leukemia in Adolescents and Young Adults
2009
Enterocolitis neutropénica en adultos con leucemia aguda o receptores de un trasplante de progenitores hematopoyéticos: estudio de 7 casos
2007
Bone Marrow Changes in Anorexia Nervosa Are Correlated With the Amount of Weight Loss and Not With Other Clinical Findings
2002
Evaluation of two replacement regimens in primary adrenal insufficiency patients. Effect on clinical symptoms, health-related quality of life and biochemical parameters
2004
Influence of highly active anti‐retroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome‐related non‐Hodgkin's lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone
2001
Pomalidomide in Combination with Low-Dose Dexamethasone: Demonstrates a Significant Progression Free Survival and Overall Survival Advantage, in Relapsed/Refractory MM: A Phase 3, Multicenter, Randomized, Open-Label Study
2012
Phase II Pethema Trial of Alternating Bortezomib and Dexamethasone As Induction Regimen Before Autologous Stem-Cell Transplantation in Younger Patients With Multiple Myeloma: Efficacy and Clinical Implications of Tumor Response Kinetics
2007
International prognostic index is the best prognostic factor for survival in patients with AIDS-related non-Hodgkin's lymphoma treated with CHOP. A multivariate study of 46 patients.
1998
Phase II Clinical and Pharmacokinetic Study of Plitidepsin 3-Hour Infusion Every Two Weeks Alone or with Dexamethasone in Relapsed and Refractory Multiple Myeloma
2010
A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis
2015
Comparison of the Results of the Treatment of Adolescents and Young Adults With Standard-Risk Acute Lymphoblastic Leukemia With the Programa Español de Tratamiento en Hematología Pediatric-Based Protocol ALL-96
2008
Aplastic anemia after non-A, non-B, and non-C hepatitis.
1994
A160 Thalidomide/Dexamethasone (TD) Versus Bortezomib (Velcade)/Thalidomide/Dexamethasone (VTD) Versus VB
2009
Bortezomib (Velcade)-Melphalan-Prednisone (VMP) Versus Velcade- Thalidomide-Prednisone (VTP) in Elderly Untreated Multiple Myeloma Patients: Which Is the Best Partner for Velcade: An Alkylating or An Immunomodulator Agent?
2008
[Cholestatic hepatitis associated with ticlopidine].
1997
Comparison of Intensive Chemotherapy, Allogeneic, or Autologous Stem-Cell Transplantation As Postremission Treatment for Children With Very High Risk Acute Lymphoblastic Leukemia: PETHEMA ALL-93 Trial
2006
Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial.
2005
A Prospective, Multicenter, Randomized, Trial of Bortezomib/Melphalan/Prednisone (VMP) Versus Bortezomib/Thalidomide/Prednisone (VTP) as Induction Therapy Followed by Maintenance Treatment with Bortezomib/Thalidomide (VT) Versus Bortezomib/Prednisone (VP) in Elderly Untreated Patients with Multiple Myeloma Older Than 65 Years.
2009
Usefulness and safety of oral cryotherapy in the prevention of oral mucositis after conditioning regimens with high‐dose melphalan for autologous stem cell transplantation for lymphoma and myeloma
2014
Feasibility and results of autologous stem cell transplantation in de novo acute myeloid leukemia in patients over 60 years old. Results of the CETLAM AML-99 protocol.
2004
Prognostic Value of Immune Profiling Multiple Myeloma Patients during Minimal Residual Disease Monitoring in the Pethema/GEM2010MAS65 Study
2015
Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus‐associated diffuse large B‐cell lymphoma: results of a phase II trial
2007
Late intensification chemotherapy has not improved the results of intensive chemotherapy in adult acute lymphoblastic leukemia. Results of a prospective multicenter randomized trial (PETHEMA ALL-89). Spanish Society of Hematology.
1998
Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma
2019